Doesn't alerting the body's immune system to attack = immuno-oncology ???
“I've covered Peregrine for many years so I remember when management claimed bavituximab worked by disrupting the growth of blood vessels. This was back when Genentech's Avastin, which works similarly, was new and exciting for investors. In the ensuing years, Peregrine management has changed the story of bavituximab's possible mechanism of action to align with whichever oncology story was buzz worthy Today, the hot trend is immuno-oncology and checkpoint inhibition, so naturally, Peregrine now claims bavituximab has magical immune-boosting qualities. The bavituximab story will change. It always does.”
April 25, 2006
Peregrine Pharmaceuticals Announces New DOD Grant to Study
Bavituximab (Tarvacin) in Breast Cancer Bavituximab works by binding to certain phospholipids, specific components of the cell structure that are usually located inside normal cells, but which become exposed on the outside of cells that line the blood vessels of tumors, creating a highly specific target for anti-cancer treatments. Once bound to the tumor blood vessels, bavituximab alerts the body's immune system to attack the tumor's blood supply, stopping the flow of oxygen and nutrients to the tumor cells and resulting in tumor cell death. By linking bavituximab to an isotope to form a radioimmunoconjugate, researchers hope to be able to use it to image tumor cells for diagnosis and disease management, as well as to destroy additional cancer cells as a result of the radiation the radioimmunoconjugate transports to the tumor blood vessels.
News 
Market Data 
Discover 
